VivoSeq
Cardiovascular

Paroxysmal Atrial Fibrillation

30

Pipeline Programs↗

12

Active Trials↗

17

Companies Involved↗

Paroxysmal atrial fibrillation is an emerging landscape with 30 programs across 17 companies. The most active players are Bristol-Myers Squibb, Ionis Pharmaceuticals, Menarini International Operations Luxembourg SA. 8 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

25/100

Mech. Concentration

14/100

Completion Rate

83/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Ionis Pharmaceuticals logo

Ionis Pharmaceuticals

1 program

Phase 2M

Menarini International Operations Luxembourg SA

1 program

Phase 2Astellas logo

Astellas

1 program

Phase 2Novo Nordisk logo

Novo Nordisk

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

45

clinical trials

Completed20 · 44%
Unknown status9 · 20%
Recruiting7 · 16%
Terminated3 · 7%
Not yet recruiting3 · 7%
Active, not recruiting2 · 4%
Other1 · 2%

Clinical Trials

Trial Activity

45 trials

Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia
Recruiting·HHippocration General Hospital·Phase 3·NCT05549752·80 enrolled
LAA Clipping Versus NOACs to Prevent Stroke in Non-paroxysmal Atrial Fibrillation.
Recruiting·CChina National Center for Cardiovascular Diseases·N/A·NCT06021808·290 enrolled
SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism
Recruiting·HHuashan Hospital·Phase 2·NCT07482020·66 enrolled
Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias Symptomatic Using Novel CARTO Technologies: REAL Registry
Recruiting·Heart Rhythm Clinical and Research Solutions, LLC·N/A·NCT04088071·20,000 enrolled
Grid eXplore Mapping Study
Recruiting·AAbbott Medical Devices·Preclinical·NCT07421076·200 enrolled
A Multicenter Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System in Patients With Atrial Fibrillation
Recruiting·BBoston Scientific Corporation·Preclinical·NCT07444320·200 enrolled
Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation - A Global Prospective Single Arm Study
Recruiting·BBoston Scientific Corporation·Preclinical·NCT07575269·571 enrolled
Clinical Benefit, Long Term Effectiveness, and Safety Outcome of Paroxysmal Atrial Fibrillation Ablation Using THERMOCOOL SMARTTOUCH®SF Catheters With Ablation Index
Active, not recruiting·BBiosense Webster, Inc.·N/A·NCT03963349·150 enrolled
Prospective, Multi-site Safety and Effectiveness Post-Approval Study of FARAPULSE Pulsed Field Ablation in Paroxysmal Atrial Fibrillation
Active, not recruiting·BBoston Scientific Corporation·N/A·NCT06431815·228 enrolled
SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation
Not yet recruiting·MMartini Hospital Groningen·Phase 4·NCT07445789·436 enrolled
Catheter Ablation Using a Novel Navigation and Imaging System
Not yet recruiting·LLUMA Vision Ltd.·N/A·NCT06895187·100 enrolled
A Multicenter Feasibility Study With the VERAFEYE Imaging and Guidance System as Anatomical Navigation System
Not yet recruiting·LLUMA Vision Ltd.·Preclinical·NCT07686328·50 enrolled
Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation
Completed·UUniversity of Michigan·Phase 2·NCT03032965·131 enrolled
Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation
Completed·Gilead logoGilead·Phase 2·NCT01522651·134 enrolled
A Trial of Circumferential Pulmonary Vein Ablation (CPVA) Versus Antiarrhythmic Drug Therapy in for Paroxysmal Atrial Fibrillation (AF)
Completed·IIRCCS San Raffaele·Phase 4·NCT00340314·198 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)